- Home
- CRIS vs CING Comparison
CRIS vs CING Comparison
Compare CRIS & CING Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRIS
- CING
- Stock Information
- Founded
- CRIS 2000
- CING 2012
- Country
- CRIS United States
- CING United States
- Employees
- CRIS N/A
- CING N/A
- Industry
- CRIS Biotechnology: Biological Products (No Diagnostic Substances)
- CING Biotechnology: Pharmaceutical Preparations
- Sector
- CRIS Health Care
- CING Health Care
- Exchange
- CRIS Nasdaq
- CING Nasdaq
- Market Cap
- CRIS 22.9M
- CING 26.7M
- IPO Year
- CRIS 2000
- CING 2021
- Fundamental
- Price
- CRIS $1.77
- CING $3.87
- Analyst Decision
- CRIS Strong Buy
- CING Strong Buy
- Analyst Count
- CRIS 2
- CING 4
- Target Price
- CRIS $16.50
- CING $31.00
- AVG Volume (30 Days)
- CRIS 75.9K
- CING 122.5K
- Earning Date
- CRIS 11-13-2025
- CING 11-06-2025
- Dividend Yield
- CRIS N/A
- CING N/A
- EPS Growth
- CRIS N/A
- CING N/A
- EPS
- CRIS N/A
- CING N/A
- Revenue
- CRIS $11,405,000.00
- CING N/A
- Revenue This Year
- CRIS $1.41
- CING N/A
- Revenue Next Year
- CRIS $7.46
- CING N/A
- P/E Ratio
- CRIS N/A
- CING N/A
- Revenue Growth
- CRIS 12.24
- CING N/A
- 52 Week Low
- CRIS $1.02
- CING $3.02
- 52 Week High
- CRIS $6.44
- CING $6.70
- Technical
- Relative Strength Index (RSI)
- CRIS 52.53
- CING 44.30
- Support Level
- CRIS $1.63
- CING $3.70
- Resistance Level
- CRIS $1.95
- CING $4.06
- Average True Range (ATR)
- CRIS 0.14
- CING 0.23
- MACD
- CRIS 0.02
- CING 0.03
- Stochastic Oscillator
- CRIS 45.59
- CING 32.72
About CRIS Curis Inc.
Curis Inc is a biotechnology company that develops and commercializes drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, solid tumors or lymphomas, hematological cancers, and others. Its pipeline products include Fimepinostat, CA-170, CA-4948, CA-327, and Erivedge.
About CING Cingulate Inc.
Cingulate Inc is a clinical-stage biopharmaceutical company utilizing its proprietary precision timed-release drug delivery platform to build and advance a pipeline of next-generation pharmaceutical products designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic area to use PTR technology to develop future product candidates.